UA84035C2 - Производные феноксиуксусных кислот, полезные как двойные агонисты активированных рецепторов пероксисомального пролифератора (ppar) - Google Patents

Производные феноксиуксусных кислот, полезные как двойные агонисты активированных рецепторов пероксисомального пролифератора (ppar)

Info

Publication number
UA84035C2
UA84035C2 UAA200605139A UAA200605139A UA84035C2 UA 84035 C2 UA84035 C2 UA 84035C2 UA A200605139 A UAA200605139 A UA A200605139A UA A200605139 A UAA200605139 A UA A200605139A UA 84035 C2 UA84035 C2 UA 84035C2
Authority
UA
Ukraine
Prior art keywords
ppar
activated receptor
peroxisome proliferator
derivatives useful
phenoxyacetic acids
Prior art date
Application number
UAA200605139A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Джи-Хонг Куо
Лан Шен
Айхуа Ванг
Ян Жанг
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of UA84035C2 publication Critical patent/UA84035C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UAA200605139A 2003-10-31 2004-10-28 Производные феноксиуксусных кислот, полезные как двойные агонисты активированных рецепторов пероксисомального пролифератора (ppar) UA84035C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51656103P 2003-10-31 2003-10-31
PCT/US2004/036028 WO2005041959A1 (en) 2003-10-31 2004-10-28 Phenoxyacetic acids derivatives useful as peroxisome proliferator-activated receptor (ppar) dual agonists

Publications (1)

Publication Number Publication Date
UA84035C2 true UA84035C2 (ru) 2008-09-10

Family

ID=34549548

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200605139A UA84035C2 (ru) 2003-10-31 2004-10-28 Производные феноксиуксусных кислот, полезные как двойные агонисты активированных рецепторов пероксисомального пролифератора (ppar)

Country Status (21)

Country Link
US (3) US7015329B2 (https=)
EP (1) EP1684752B1 (https=)
JP (1) JP2007527416A (https=)
KR (1) KR20060109925A (https=)
CN (1) CN1897939A (https=)
AR (1) AR046311A1 (https=)
AT (1) ATE362367T1 (https=)
AU (1) AU2004285530A1 (https=)
BR (1) BRPI0416106A (https=)
CA (1) CA2544317A1 (https=)
CR (1) CR8377A (https=)
DE (1) DE602004006529T2 (https=)
EA (1) EA009804B1 (https=)
EC (1) ECSP066536A (https=)
ES (1) ES2287786T3 (https=)
IL (1) IL175310A0 (https=)
NO (1) NO20062511L (https=)
TW (1) TW200528438A (https=)
UA (1) UA84035C2 (https=)
WO (1) WO2005041959A1 (https=)
ZA (1) ZA200604420B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JP2007527416A (ja) * 2003-10-31 2007-09-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ペルオキシソーム増殖因子活性化受容体(ppar)二重作動薬として有用なフェノキシ酢酸誘導体
WO2006042245A1 (en) * 2004-10-11 2006-04-20 Dr. Reddy's Laboratories Ltd. Novel isoxazole compounds having ppar agonist activity
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
CA2663115C (en) 2006-09-08 2015-04-28 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
WO2008030604A2 (en) 2006-09-08 2008-03-13 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced brain disease
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP3053440B1 (en) 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US8461183B2 (en) * 2008-05-26 2013-06-11 Genfit PPAR agonist compounds, preparation and uses
JP5996532B2 (ja) 2010-07-15 2016-09-21 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 有害生物防除剤としての新規複素環式化合物
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
SI2841437T1 (sl) 2012-04-26 2017-09-29 Bristol-Myers Squibb Company Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov
CA2871640A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Par4 agonist peptides
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물
WO2024153134A1 (zh) * 2023-01-18 2024-07-25 哈尔滨三联药业股份有限公司 五元杂环类化合物及其医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6242493B1 (en) 1998-03-13 2001-06-05 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU4167099A (en) 1998-06-19 2000-01-05 Nissan Chemical Industries Ltd. Heterocyclic compounds as hypoglycemic agents
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
PL351470A1 (en) 1999-04-28 2003-04-22 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
US6417212B1 (en) * 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
EP1310494B1 (en) * 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
EP1578715B1 (en) 2002-12-20 2011-03-02 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
JP2007527416A (ja) * 2003-10-31 2007-09-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ペルオキシソーム増殖因子活性化受容体(ppar)二重作動薬として有用なフェノキシ酢酸誘導体

Also Published As

Publication number Publication date
US20050096362A1 (en) 2005-05-05
AU2004285530A1 (en) 2005-05-12
CN1897939A (zh) 2007-01-17
TW200528438A (en) 2005-09-01
KR20060109925A (ko) 2006-10-23
NO20062511L (no) 2006-07-27
US20090131489A1 (en) 2009-05-21
WO2005041959A1 (en) 2005-05-12
ECSP066536A (es) 2006-12-20
EA009804B1 (ru) 2008-04-28
IL175310A0 (en) 2006-09-05
ATE362367T1 (de) 2007-06-15
US7015329B2 (en) 2006-03-21
BRPI0416106A (pt) 2007-01-02
AR046311A1 (es) 2005-11-30
DE602004006529T2 (de) 2008-01-31
DE602004006529D1 (de) 2007-06-28
US20060074246A1 (en) 2006-04-06
US7498351B2 (en) 2009-03-03
EP1684752B1 (en) 2007-05-16
EA200600878A1 (ru) 2006-10-27
CR8377A (es) 2008-11-24
ES2287786T3 (es) 2007-12-16
ZA200604420B (en) 2007-10-31
CA2544317A1 (en) 2005-05-12
EP1684752A1 (en) 2006-08-02
JP2007527416A (ja) 2007-09-27

Similar Documents

Publication Publication Date Title
UA84035C2 (ru) Производные феноксиуксусных кислот, полезные как двойные агонисты активированных рецепторов пероксисомального пролифератора (ppar)
SG145752A1 (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MX2009011816A (es) Derivados de piridina.
UA94749C2 (en) Benzimidazole modulators of vr1
MXPA05012840A (es) Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades.
PH12013500745A1 (en) Azaadamantane derivatives and methods of use
SE0301010D0 (sv) Novel compounds
EA200970156A1 (ru) Пиридизиноновые производные
MX2010001576A (es) Compuestos 3´sustituidos que tienen afinidad con el receptor 5-hidroxitriptamina 6 (5-ht6).
TW200602330A (en) Compounds and compositions as PPAR modulators
TW200637827A (en) Processes for preparing substituted phenylpyrazole ureas
MX2009012471A (es) Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6.
TW200600505A (en) Compounds and compositions as ppar modulators
TW200726739A (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
EA200901391A1 (ru) Пиримидинилпиперазины, применимые в качестве лигандов рецепторов d/d
WO2007073303A3 (en) Novel benzimidazole derivatives as vanilloid receptor 1 (vrl) inhibitors
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
TW200624117A (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
PL376718A1 (pl) Nowe związki, ich wytwarzanie i stosowanie
WO2007049158A3 (en) Ppar modulating biaromatic compounds
SG149041A1 (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
IL165220A0 (en) Novel compounds, their use and preparation
TW200621692A (en) 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2007075749A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
BR0315667A (pt) Composto, uso de um composto, composição farmacêutica, e, método para o tratamento